www.lilly.co.uk

Eli Lilly and Company Limited
Lilly Research Centre
Erl Wood Manor
Sunninghill Road
Windlesham, Surrey GU20 6PH
England

Eli Lilly European Regulatory Team

Phone - +44 (0) 1276 483000

13 March 2007

Dr. Daniel Brasseur
European Medicines Agency (EMEA)
7 Westferry Circus
Canary Wharf
London
E14 4HB
UK

Subject: Withdrawal of ARXXANT™ (ruboxistaurin), 32 mg, film-coated tablets
EMEA/H/C/000753

Dear Dr. Brasseur,

I would like to inform you that, at this point of time, Eli Lilly Nederland B.V. has taken the decision to withdraw the application for Marketing Authorisation of ARXXANT™ (ruboxistaurin), 32 mg, film-coated tablets, which was intended to be used for the treatment of diabetic retinopathy in adult patients with moderate to severe non-proliferative diabetic retinopathy.

This withdrawal is based on the request for additional data, which we are not able to provide within the timeframe allowed in the Centralised Procedure.

This decision has no immediate consequences for patients enrolled in ongoing clinical trials.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,

European Regulatory Affairs